Natural product inhibitors of ocular angiogenesis

dc.contributor.authorSulaiman, Rania S.
dc.contributor.authorBasavarajappa, Halesha D.
dc.contributor.authorCorson, Timothy W.
dc.contributor.departmentDepartment of Ophthalmology, IU School of Medicineen_US
dc.date.accessioned2015-06-30T19:37:30Z
dc.date.available2015-06-30T19:37:30Z
dc.date.issued2014-12
dc.description.abstractNatural products are characterized by high chemical diversity and biochemical specificity; therefore, they are appealing as lead compounds for drug discovery. Given the importance of angiogenesis to many pathologies, numerous natural products have been explored as potential anti-angiogenic drugs. Ocular angiogenesis underlies blinding eye diseases such as retinopathy of prematurity (ROP) in children, proliferative diabetic retinopathy (DR) in adults of working age, and age-related macular degeneration (AMD) in the elderly. Despite the presence of effective therapy in many cases, these diseases are still a significant health burden. Anti-VEGF biologics are the standard of care, but may cause ocular or systemic side effects after intraocular administration and patients may be refractory. Many anti-angiogenic compounds inhibit tumor growth and metastasis alone or in combination therapy, but a more select subset of them has been tested in the context of ocular neovascular diseases. Here, we review the promise of natural products as anti-angiogenic agents, with a specific focus on retinal and choroidal neovascularization. The multifunctional curcumin and the chalcone isoliquiritigenin have demonstrated promising anti-angiogenic effects in mouse models of DR and choroidal neovascularization (CNV) respectively. The homoisoflavanone cremastranone and the flavonoid deguelin have been shown to inhibit ocular neovascularization in more than one disease model. The isoflavone genistein and the flavone apigenin on the other hand are showing potential in the prevention of retinal and choroidal angiogenesis with long-term administration. Many other products with anti-angiogenic potential in vitro such as the lactone withaferin A, the flavonol quercetin, and the stilbenoid combretastatin A4 are awaiting investigation in different ocular disease-relevant animal models. These natural products may serve as lead compounds for the design of more specific, efficacious, and affordable drugs with minimal side effects.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationSulaiman, R. S., Basavarajappa, H. D., & Corson, T. W. (2014). Natural product inhibitors of ocular angiogenesis. Experimental eye research, 129, 161-171.en_US
dc.identifier.urihttps://hdl.handle.net/1805/6514
dc.publisherScienceDirecten_US
dc.relation.isversionof10.1016/j.exer.2014.10.002en_US
dc.relation.journalExperimental Eye Researchen_US
dc.rightsIUPUI Open Access Policyen_US
dc.sourceAuthoren_US
dc.subjectocular angiogenesisen_US
dc.subjectantiangiogenic drugsen_US
dc.titleNatural product inhibitors of ocular angiogenesisen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Sulaiman_2014_natural.pdf
Size:
440.43 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
nihms633792.pdf
Size:
339.16 KB
Format:
Adobe Portable Document Format
Description:
Author's manuscript (NIH Public Access Version)
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: